Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Its once-weekly injectable format supports higher adherence levels compared to older daily formulations, making it well suited for long-term obesity management in home-delivery settings
Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit
Tirzepatide es un medicamento inyectable aprobado por la FDA para el tratamiento de la diabetes tipo 2 (bajo el nombre comercial Mounjaro) y para el manejo del peso en adultos con obesidad (IMC 30 kg/m) o sobrepeso (IMC 27 kg/m) con al menos una comorbilidad relacionada con el peso (como Zepbound)
This side effect is less common than nausea, but it still affects some patients
US$ 22.05
US$ 22.43
US$ 25.95
US$ 26.08
